People in the News

Aug 18, 2017

Richard Larkin

Chembio Diagnostics CFO Richard Larkin has told the firm he will retire by the end of the year. An external search to replace Larkin, who is also an executive vice president at Chembio, will begin immediately. Larkin will continue as CFO until Dec. 31, 2017, or until a successor is found, whichever is earlier. 

Aug 16, 2017

Bob King

Bob King has been named vice president of sales at Episona, where he will oversee the commercial expansion of the company's Seed test for evaluating male factor infertility and embryo quality. Most recently, he was director of business development and strategic accounts at Good Start Genetics. Previously, he was area sales director at Natera.

Aug 14, 2017

Sherrie Perkins, Andrew Theurer, Edgar Braendle

Sherrie Perkins has accepted the postion of CEO of ARUP Laboratories, while Andrew Theurer has accepted the position of president at the lab. They replace Edgar Braendle who served in both positions during the past year. Braendle is leaving ARUP to pursue other opportunities and rejoin his family in New Jersey, ARUP said. Perkins was previously senior vice president of R&D at ARUP, as well as professor, vice chair, and division chief of clinical pathology. She is a tenured professor at the University of Utah School of Medicine. Theurer was senior VP and CFO at ARUP. 

Aug 08, 2017

John Rice

Meridian Bioscience has appointed John Rice as an independent director. Rice joins Meridian from CincyTech, a firm that provides advice and capital to entrepreneurs and helps research institutions commercialize technology through startups. He has served as the director of life sciences since 2014. Rice is also the founder and, since 2003, managing partner of Triathlon Medical Ventures Partners, a venture capital firm that invests equity capital in early- and expansion-stage life science companies.

Aug 07, 2017

Paul Marr

MDxHealth has appointed Paul Marr to the post of executive VP of sales for North America. Marr previously served as VP of sales, North America for Beckman Coulter, and also has worked for Hologic, Gen-Probe, Leica Biosystems, Bayer Diagnostics, and Siemens Healthcare. He joins MDxHealth, which is based in Belgium, in conjunction with the firm's expansion of its US sales force to 50 representatives.

Aug 04, 2017

Madhuri Hegde

Madhuri Hegde has has been elected to the ACMG Foundation for Genetic and Genomic Medicine Board of Directors, the supporting educational foundation of the American College of Medical Genetics and Genomics. Hegde joined PerkinElmer in 2016 as vice president and CSO of Global Genetics Laboratory Services. She also is an adjunct professor of human genetics at Emory University. Previously, Hegde was executive director and CSO at Emory Genetics Laboratory in Atlanta; professor of human genetics and pediatrics at Emory University; and assistant professor of human genetics and senior director at Baylor College of Medicine in Houston.

Aug 03, 2017

Marijn Dekkers

Quanterix named Marijn Dekkers to its board. He is currently a board member at General Electric and is chairman of Unilever. He was previously CEO of Bayer and of Thermo Fisher Scientific. 

Aug 02, 2017

Bill Rastetter, Jeff Huber, Ken Drazan

Grail, a company aiming to develop a blood test for early cancer detection, has named Bill Rastetter, current chair of the company's board of directors, as its new CEO. Founding CEO Jeff Huber is now vice chairman of the board of directors, and Ken Drazan has been promoted from chief business officer to president.

Aug 02, 2017

Abraham Tzou

Freenome has appointed Abraham Tzou as its VP of regulatory affairs. Tzou will be in charge of regulatory strategy for products developed by Freenome and manage submissions to the US Food and Drug Administration and oversight bodies abroad.  

Tzou joins Freenome after serving as a medical officer at the FDA's Center for Devices and Radiological Health, where he led the clinical evaluation of in vitro diagnostics for cancer screening and prognosis, genetic disorders, and companion tests. During his tenure at the agency, he received commendation for his part in a team that reviewed Exact Sciences' non-invasive, colon cancer screening test Cologuard for parallel review. 

Freenome is developing a non-invasive cancer screening technology that involves genome-wide sequencing and a computational system, called Adaptive Genomics Engine. The company is interested in pursuing Parallel Review for this technology, which if successful, would enable simultaneous FDA approval and a national coverage determination from the Centers for Medicare & Medicaid Services.

Jul 31, 2017

Romney Humphries

Accelerate Diagnostics has appointed Romney Humphries as chief scientific officer. Prior to joining Accelerate Diagnostics, Humphries served as section chief for clinical microbiology and assistant clinical professor in the department of pathology and laboratory medicine at the UCLA Medical Center. Humphries currently serves on several committees and working groups for organizations including the American Society for Microbiology, the Clinical Laboratory and Standards Institute, the US Food and Drug Administration, and the World Health Organization.

Jul 26, 2017

Scott Howell

Tenet Diagnostics has appointed Scott Howell its CMO. He was most recently executive medical director at Heritage Provider Network. He also continues to practice at Kaiser Permanente Los Angeles Medical Center in the addiction medicine department. He was previously national senior medical director and chief medical officer Network and Population Health, Optim Insight, regional CMO Northeast region of Americhoice, and national medical director of managed care for AIDS Healthcare Foundation. 

Jul 25, 2017

David Barka, Nikhil Vazirani

Erba Diagnostics said that effective Aug. 1, David Barka will become the interim CEO and Nikhil Vazirani will join the firm's board. Barka has been the vice president of Calbiotech since 2004, and as president of Calbiotech Veterinary Diagnostics since 2017. He also has been president of Microplate Dispensers, dba Moduline Systems, since 2013. He plans to continue serving in those roles, Erba said. Vazirani has been the managing director of Erba Diagnostics Mannheim since April 2016, and a director of Erba Diagnostics UK and the interim CEO of Erba Lachema since this past February. He plans to continue serving in those roles. 

Jul 24, 2017

Richard Wenstrup

Richard Wenstrup was appointed CMO of Oxford Immunotec. He has more than 20 years of clinical leadership experience, including more than a decade in the diagnostics space. Wenstrup was most recently executive vice president and CMO of Myriad Genetics. Previously, he was CMO of Myraid Genetic Laboratories. 

Jul 24, 2017

Kieran Murphy, Stephen Kanovsky

Kieran Murphy has resigned from the board of NeoGenomics following his appointment as president and CEO of GE Healthcare. NeoGenomics said in a document filed with the US Securities and Exchange Commission that Murphy resigned due to the time demands of his new job, and added that it has appointed Stephen Kanovsky to fill Murphy's position on the board. He is general counsel of GE unit Global Innovation of GE Healthcare.

Jul 21, 2017

Thomas Loewald

Thomas Loewald, senior vice president and chief commercial officer at Thermo Fisher Scientific since early 2016, will resign from the company, effective September 1. He joined the firm's Explosives Detection business in 2002 and held various positions over the years, including senior vice president and president of Laboratory Products. Prior to that, he was vice president of sales and marketing for Tyco International.

Jul 20, 2017

Mark Stevenson

Mark Stevenson has been promoted to executive vice president and chief operation officer of Thermo Fisher Scientific, effective August 1. In his new role, he will oversee operations of the company's Laboratory Products and Analytical Instruments businesses, in addition to the Life Sciences Solutions business. Since 2014, when Thermo Fisher acquired Life Technologies, Stevenson has been executive vice president and president of Life Sciences Solutions. Prior to that, he was president and chief operating officer of Life Technologies, and before that, he was president and COO of Applied Biosystems.

Jul 19, 2017

Lew Titterton

Lew Titterton has rejoined the board of Itus. He was previously on the firm's board from 2010 to 2016, and was its chairman during the last four years of his previous tenure. He was also a director at Itus between 1999 and 2003. Titterton is currently chairman of the board at NYMED.

Jul 18, 2017

Anna Chérouvrier Hansson, Henrik Appelgren

Anna Chérouvrier Hansson is joining SenzaGen as the firm's chief commercial officer, and Henrik Appelgren will become its chief scientific officer. The firm said that the appointments are the final steps as it prepares to commercialize its GARD tests and to list on the Nasdaq First North. Hansson most recently was the director of marketing at Camurus. She begins her new job on Aug. 15. Appelgren has been with the Swedish Chemicals Agency for 15 years, where he was Sweden's national coordinator in the OECD Test Guideline Programme. He joins SenzaGen on Sept. 4. 

 

Jul 17, 2017

Stephen Pereira

Stephen Pereira has been appointed to Immunovia's scientific advisory board. Pereira is a professor of hepatology and gastroenterology at University College London and is an honorary consultant in pancreaticobiliary medicine at UCL Hospitals and the Royal Free Hospital. 

Jul 07, 2017

Matthias Raquet

Oneservice, a Swiss company offering complete managed service solutions, consulting, and learning for the life science, diagnostics, and medical device industries, has appointed Matthias Raquet as CEO. Raquet joins Oneservice from Qiagen, where he has worked since 2001, most recently as vice president and head of global service solutions and global customer management. Prior to Qiagen he worked in various management roles at Amersham Pharmacia.

Jul 07, 2017

Amit Kumar, Robert Berman, Mike Catelani

Amit Kumar was named president and CEO of Itus, which is developing blood-based solid tumor cancer diagnostics. He replaces Robert Berman, who resigned as president, CEO, and as a director. Kumar, formerly CEO of CombiMatrix, has been the executive chairman of Itus for the past year, and has been a director since joining the firm in 2012. Also, Mike Catelani, Itus' CFO, has been promoted to chief operating officer. 

Jul 06, 2017

Richard Davis

Qualigen announced Richard Davis has been elected to its board, effective June 26. David is an associate clinical professor of urology at the David Geffen School of Medicine at the University of California, Los Angeles, as well as chief of surgery at Motion Picture and Television Hospital. He is on the staff of several hospitals, as well. 

Jul 06, 2017

Gail Page

Gail Page has joined the board of Chembio Diagnostics. Page is the founder of Vineyard Investment Advisors, and previously was president and CEO of Vermillion. She also served as executive vice president and COO of Luminex. 

Jul 05, 2017

Patrick Kennedy

Former Congressman Patrick Kennedy has joined the board of Medibio, an Australian firm developing biomarker-based tests for the diagnosis and management of mental disorders, including depression and chronic stress. Kennedy was an eight-term member of Congress, where he represented Rhode Island. 

 

Jul 05, 2017

Chad Brown

NanoString Technologies has appointed Chad Brown senior vice president of sales and marketing. With more than 35 years of experience in life science tools and clinical diagnostics, Brown most recently served as the president and head of commercial operations for North America at Qiagen. Prior to that, Brown was with Roche Diagnostics Corporation, where he held a series of commercial leadership positions in the applied sciences and centralized diagnostics businesses. He has also held sales leadership positions in several medical device and healthcare companies, including Chiron Diagnostics, Rotech Healthcare, Apria Healthcare, and Humana.

Brown succeeds Barney Saunders, who is expected to stay with NanoString for a three-month transition period before pursuing other professional opportunities.

Pages